Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement by Bien, C. G. et al.
doi:10.1093/brain/awh415 Brain (2005), 128, 454–471
Pathogenesis, diagnosis and treatment of
Rasmussen encephalitis
A European consensus statement
C. G. Bien,1 T. Granata,2 C. Antozzi,2 J. H. Cross,3 O. Dulac,4 M. Kurthen,1 H. Lassmann,5
R. Mantegazza,2 J.-G. Villemure,6 R. Spreafico2 and C. E. Elger1
Correspondence to: Dr Christian G. Bien, University of
Bonn, Department of Epileptology, Sigmund-Freud-Str. 25,
53105 Bonn, Germany
E-mail: christian.bien@ukb.uni-bonn.de
C. G. Bien and T. Granata contributed equally to this
manuscript.
1University of Bonn, Department of Epileptology, Bonn,
Germany, 2Instituto Nazionale Neurologico ‘C. Besta’,
Milan, Italy, 3Institute of Child Health and Great Ormond
Street Hospital for Children NHS Trust, London, UK,
4Service de Maladies Me´taboliques et Neurologie Hoˆpital
Necker Enfant Malades, Paris, France, 5Medical University
of Vienna, Brain Research Institute, Vienna, Austria, and
6Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland
Summary
Rasmussen encephalitis (RE) is a rare but severe immune-
mediated brain disorder leading to unilateral hemispheric
atrophy, associated progressive neurological dysfunction
and intractable seizures. Recent data on the pathogenesis
of the disease, its clinical and paraclinical presentation,
and therapeutic approaches are summarized. Based on
these data, we propose formal diagnostic criteria and a
therapeutic pathway for the management of RE patients.
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Introduction
In 1958, Theodore Rasmussen and co-workers from the
Montreal Neurological Institute reported three patients
suffering from ‘focal seizures due to chronic localized
encephalitis’ (Rasmussen et al., 1958). Since the late
1980s, most researchers and clinicians have adopted the
term Rasmussen encephalitis (RE) or Rasmussen syndrome
for this condition (Piatt et al., 1988; Andermann, 1991). In
recent years, important new insights have added to our under-
standing of the pathophysiology, the diagnosis and the
management of the condition. Here, we present a summary
of the existing knowledge and experience with an emphasis
on the clinical management of RE patients. The consensus
proposed here for the diagnosis and therapy of RE results
from a symposium entitled ‘Current concepts and controversies
in Rasmussen’s encephalitis’ held at the 6th European
Congress on Epileptology in Vienna on 1 June 2004.
Aetiology and pathogenesis of RE
RE is a rare disease that should be envisaged as sporadic,
since there is no evidence for a genetic component
(Andermann et al., 1991; Grenier et al., 1991). There is, at
present, no conclusive evidence why and how RE starts.
A viral aetiology was already suggested by Rasmussen based
on the constituents of the immune reaction in the brains such
as lymphocyte infiltration and microglial nodules (Rasmussen
et al., 1958). The similarities of RE and Russian spring sum-
mer meningoencephalitis, which is caused by a flavivirus, fur-
ther supported this hypothesis (Asher and Gajdusek, 1991).
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However, so far all attempts to identify a pathogenic viral
agent have been contradictory and inconclusive (Friedman
et al., 1977; Rasmussen, 1978; Walter and Renella, 1989;
Power et al., 1990; Farrell et al., 1991; Gilden and Lipton,
1991; Vinters et al., 1993; McLachlan et al., 1993, 1996;
Atkins et al., 1995; Jay et al., 1995). Available data continue
to suggest an immune basis to the pathogenesis of RE. Evid-
ence has emerged both of a role for humoral factors, namely
autoantibodies, as well as more recently T lymphocytes,
namely cytotoxic T cells.
Humoral autoimmunity
In the course of raising antibodies against subunit 3 of the
ionotropic glutamate receptor (GluR3) in rabbits, two out of
four rabbits immunized with the GluR3 fusion protein
developed seizures. Histopathological examination of their
brains revealed bihemispheric inflammatory changes which
were reported to mimic those of RE. Subsequent studies in
patients showed that three out of four RE patients’ sera
harboured those GluR3 antibodies. One of these patients
improved transiently after plasma exchange (Rogers et al.,
1994). Other reports of temporary or longer lasting improve-
ment of the symptoms of RE by removal of antibodies from
the circulation have subsequently been published (Andrews
et al., 1996; Palcoux et al., 1997; Antozzi et al., 1998;
Granata et al., 2003a). How autoantibodies might lead to
brain tissue destruction and seizure activity has been
answered in two different ways: Some authors report evid-
ence that GluR3 antibodies mediate an excessive, cytotoxic
activation of the glutamate receptor using in vitro (Twyman
et al., 1995; Levite et al., 1999) and in vivo systems (Levite
and Hermelin, 1999). Others have observed signs of a
complement activation on neurons and glial cells in animals
and affected humans without measurable channel activating
properties (He et al., 1998; Whitney et al., 1999; Whitney and
McNamara, 2000; Frassoni et al., 2001).
More recently, the specificity of GluR3 autoantibodies for
RE has been challenged. Two groups, both using an enzyme-
linked immunosorbent assay approach to detect antibodies
against different GluR3 peptides, reached congruent results:
GluR antibodies (in serum, but similar results in CSF sam-
ples) are not present in all RE patients, and they are found in
other epilepsy forms in a comparable proportion (Wiendl
et al., 2001; Mantegazza et al., 2002). A subsequent report
even questioned these partially positive results by use of five
different approaches to test for GluR3 antibodies (Watson
et al., 2004). However, further arguments for a humoral or
complement-dependent pathogenesis (not necessarily medi-
ated by GluR3 antibodies) have been provided: Yang and
co-workers described a RE case with antibodies against
the cytosolic presynaptic protein munc-8 (Yang et al.,
2002). In brain samples of four RE patients, Baranzini and
colleagues studied the immunoglobulin heavy chain CDR3
(IgGVH-CDR3) repertoire and analysed it by size spectra-
typing and sequencing. They found evidence for clonally
expanded B lymphocytes in RE, but the IgGVH-CDR3
sequences were diverse among the four cases. Possible reas-
ons put forward for this included determinant spreading and
genetic or antigenic heterogeneity (Baranzini et al., 2002).
Xiong and colleagues showed that the sequential application
of the complement cascade proteins C5b6, C7, C8 and C9,
which are known to lead to the formation of the membrane
attack complex (MAC), into the hippocampi of rats lead to
epileptic seizures and massive necrotic hippocampal cell
death (Xiong et al., 2003).
Taken together, there is highly conflicting evidence regard-
ing the pathogenic effect and even the mere presence of
elevated GluR3 autoantibodies in RE. This does not exclude
that other humoral mechanisms may contribute to the patho-
genesis of RE. Future antibody research in RE will probably
concentrate on detecting possibly pathogenic antibodies other
than GluR3 antibodies (Lang et al., 2004).
T cell mediated cytotoxicity in RE
In the first extensive histopathological-immunohistochemical
study on RE brains, it was found that the majority of the
inflammatory round cells were T lymphocytes (Farrell
et al., 1995). Consecutively, Li et al. (1997) analysed these
T cells with regard to their T cell receptors (TCR). This group
studied TCR expression in RE brain samples by quantitative
assessment of TCR Vb gene transcripts. A restricted (oligo-
clonal) BV family usage was found; however, the TCR Vb
families that were predominantly expressed displayed a lim-
ited size heterogeneity and extensive repetition of in-frame
CDR3 nucleotide motifs compared with controls. These find-
ings suggest that the local immune response in RE includes
restricted T cell populations that have likely expanded
from a few precursor T cells responding to discrete antigenic
epitopes (Li et al., 1997). Further immunohistochemical
studies on RE brain specimens provided evidence of a
Granzyme B (GrB) mediated cytotoxic T lymphocyte
(CTL) attack against neurons. All elements of such a reaction
could be documented in RE: T cells containing GrB granules,
target cells (here neurons) expressing major histo-
compatability complex (MHC) class I and dying by apop-
tosis. This CTL mechanism is suitable to explain the
progressive brain tissue loss. However, it cannot directly
account for the epileptic activity in RE brains and there is,
at present, no evidence against which antigen(s) the CTLs are
directed (Bien et al., 2002a).
Gahring and co-workers have provided a potential link
between the GluR3-autoantibody-hypothesis and the findings
regarding CTLs (Gahring et al., 2001): they found that the
immunogenic section of the GluR3 protein could be exposed
to the immune system only after cleavage of GluR3 by GrB.
A necessary prerequisite for this is that an internal N-
linked glycosylation sequence within the GluR3-GrB
recognition sequence (ISND*S) is not glycosylated. This
observation concords with an earlier study indicating a
possible interrelationship of GrB + proteolytic effects and a
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humoral autoimmunity in systemic autoimmune diseases
(Casciola-Rosen et al., 1999). However, in view of the
doubtful relevance of the GluR3 antibodies the study by
Gahring and colleagues can, at present, not serve as a valid
explanation for RE pathogenesis.
RE as an epileptic encephalopathy
In analogy to other conditions of childhood epilepsies with
progressive neurological deterioration, it has been suggested
that in RE, too, the epileptic activity itself may contribute to
the functional decline (Nabbout and Dulac, 2003). After a few
months, partial motor seizures affect, in an apparently inde-
pendent fashion, various areas of the same side of the body,
the affected part of the body increasing over time. EEG
recordings show unilateral deterioration of the background
activity and repeat focal rhythmic discharges migrating from
one area of the cortex to another on the affected side, often
without clear correspondence to the clinical events and, as
with the clinical events, the discharges persist during sleep.
Focal motor deficit usually follows the onset of epilepsy. The
strength of the affected part of the body decreases and the
patient progressively becomes hemiparetic. However, the
downhill course of motor abilities on the affected side is
irregular and depends of the intensity of the seizure activity,
with periods of improvement when there is transient control
of the seizures (Chinchilla et al., 1994). It is thus often
difficult to determine whether the motor defect is purely
functional because of frequent seizures and therefore revers-
ible, or if it results from loss of cortical cells. Nevertheless,
steroids given early in the course of the disease are able to
reduce the severity of the deficit, particularly for children
with onset after 4 years of age, provided seizure activity is
brought under control (Chinchilla et al., 1994).
Whether humoral, cellular or mixed, the immune effector
cells or antibodies originate from the blood stream. Since in
Rasmussen disease the brain involvement is mainly unilat-
eral, some factor additional to autoimmunity must contribute
to the pathogenesis in order to determine unilaterality. Focal
epilepsy could be this factor. Indeed, seizure discharges are
known to functionally damage the blood–brain barrier (BBB).
Humoral compounds could therefore reach the neurons and
damage them, increasing the epileptic activity and the func-
tional damage to the BBB, closing thereby a vicious circle
(Andrews et al., 1996). This would be of importance for
antibodies, as they cannot cross an intact BBB, in contrast
to activated T cells. The concept of epileptogenic encephalo-
pathy would, in this disorder, have a larger and specific
meaning: seizures would not only generate functional defect,
but also contribute to the immunologically generated neur-
onal loss and brain atrophy.
In conclusion, the precise nature and sequence of the
pathogenetically relevant processes have not yet been agreed
on. Some authors (Antel and Rasmussen, 1996; Krauss et al.,
1996; Baranzini et al., 2002) ask if, in all RE patients and
indeed at all stages of their disease, a uniform process takes
place. However, this cannot be clarified at this stage and there
are at present no data to distinguish potential pathogenetic
subgroups, especially not with regard to specific therapeutic
strategies.
Clinical features
Clinical disease course
Reported cohorts of individuals with RE are not large, but
conclusions about the natural history of the disease can be
drawn (Oguni et al., 1991; Bien et al., 2002c,d; Chiapparini
et al., 2003; Granata et al., 2003b). Although seen in adult-
hood, the majority present in childhood with an average age
at disease manifestation of 6 years of age (Oguni et al., 1991).
Three disease stages have recently been proposed. Initially,
there may be a rather non-specific ‘prodromal stage’ with a
relatively low seizure frequency and rarely mild hemiparesis
with a median duration of 7.1 months (range: 0 months to
8.1 years). Following this, all patients enter an ‘acute stage’ of
the disease, although for a third of cases, this appears to be the
initial clinical disease manifestation. It is characterized by
frequent seizures, mostly simple partial motor seizures often
in the form of epilepsia partialis continua (EPC). The neuro-
logical deterioration becomes manifest by progressive
hemiparesis, hemianopia, cognitive deterioration and, if the
language dominant hemisphere is affected, aphasia (Oguni
et al., 1991). The median duration of this stage is 8 months
(range 4–8 months). After that, the patients pass into the
‘residual stage’ with permanent and stable neurological defi-
cits and still many seizures, although less frequent than in the
acute stage. At this stage, not all the patients are hemiplegic
(Bien et al., 2002d ). The large time ranges for the duration of
the disease stages indicate the high variability of speed and
severity of the destructive process in different patients. For
clinical monitoring of the disease progress, hemiparesis is the
most useful marker as this feature is most consistently found,
and it allows quantitative evaluation, even in children. Since
it can be increased by additional transient postictal paresis in
cases with motor seizures, several examinations—especially
in periods without high frequency of seizures—may be
necessary to obtain a reliable impression of the degree of
permanent motor impairment. In addition, periodic assess-
ment of neuropsychological performance is recommended
in order to detect cognitive decline, especially in cases with-
out overt hemiparesis, such as those of temporal lobe origin
(Hennessy et al., 2001).
Epileptic seizures
Three features of the epilepsy in RE patients have been noted:
(i) the polymorphism of seizures in a given patient; (ii) the
frequent occurrence of EPC; and (iii) the medical intractab-
ility of seizures, particularly of EPC (see the section on
Treatment below). The different semiologies of seizures,
often noted on longitudinal evaluation of patient records
(Granata et al., 2003b), is best explained as a ‘march (of
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the epileptic focus) across the hemisphere’ (Oguni et al.,
1991). Congruent observations have been made by serial
neuroimaging studies. However, apart from the rare cases
of bilateral RE, all seizures originate in one hemisphere.
Oguni and co-workers quantified the clinical seizure types
during the disease course of their series of 48 patients. Simple
partial motor seizures involving one side of the body were the
most common (occurring in 77% of cases), followed by sec-
ondarily generalized tonic clonic seizures (42%), complex
partial seizures (19% with automatisms and 31% with sub-
sequent unilateral motor involvement), postural seizures
probably originating in the supplementary motor region
(24%) and somatosensory seizures (21%) (Oguni et al.,
1991).
EPC has been reported to occur in 56–92% of patients at
some time during their disease course (Oguni et al., 1991;
Honavar et al., 1992; Bien et al., 2002d; Granata et al.,
2003b). EPC was originally described in Russian adults
(Koshewnikow, 1895) suffering from Russian spring-
summer encephalitis (Omorokow, 1927) and has subseq-
uently caused extensive discussions regarding its nature
and origin. This debate cannot be summarized here. Today,
EPC is most commonly viewed as cortical and epileptic
with mainly three peculiarities:
(i) it cannot be influenced by anticonvulsive drugs;
(ii) unlike other motor seizures, EPC does not have the
general tendency to spread (as Jacksonian seizures
do—even though Jacksonian seizures may evolve
from time to time from EPC);
(iii) it does not stop after the usual short time of focal motor
seizures. (Juul-Jensen and Denny-Brown, 1966; Bancaud
et al., 1977; Thomas et al., 1977; Wieser et al., 1978;
Cockerell et al., 1996).
Less common manifestations of RE
Adolescent and adult cases
Even though RE has for a long time been considered as a
childhood disease, adolescent and adult patients have been
described by several groups (Gray et al., 1987; Oguni et al.,
1991; McLachlan et al., 1993; Hart et al., 1994b, 1997;
Larner et al., 1995; Krauss et al., 1996; Bhatjiwale et al.,
1998; Leach et al., 1999; Bien et al., 2002d ) and based on
figures from Montreal, can be estimated to account for about
10% of all RE cases (Oguni et al., 1991; Hart et al., 1997).
The oldest patient reported so far was 54-years-old
(Vadlamudi et al., 2000). The Montreal group described
13 patients, who had in common a localization-related seizure
disorder and the pathological features of chronic encephalitis.
Even if one excludes two highly atypical cases (numbers 4
and 13, who obviously had another disease, as already
considered by the authors), the similarities between the
‘true’ adolescent/adult and the childhood RE cases were
more obvious than the differences (Hart et al., 1997).
They appear to have a more protracted and milder clinical
course with less residual functional deficits and lower degrees
of hemiatrophy and more frequent occipital lobe seizure onset
(Hart et al., 1997; Bien et al., 2002d ), but identical histo-
pathological as well as clinical, electrophysiological and
neuroimaging findings.
Dual pathology
Cases with dual pathology (RE plus low grade tumour,
cortical dysplasia, tuberous sclerosis, vascular abnormalities
or old ischaemic lesions) have been described (Hart et al.,
1998; Firlik et al., 1999; Palmer et al., 1999; Thom et al.,
1999; Bien et al., 2002d ). In the Montreal series, 10% of
cases had dual pathology (Hart et al., 1998). The diagnosis of
dual pathology has, in part, been suspected based on MRI
findings, but always been confirmed by histopathology
(biopsy or resective epilepsy surgery).
Bilateral RE
Several clinical and electrophysiological features have
suggested bilateral cerebral affection in otherwise typical
unihemispheric cases, e.g. secondary spread of focal seizures
to the contralateral side, interictal epileptiform abnormalities
on the contralateral side (see below), or mild contralateral
atrophy (Hart and Andermann, 2000). A recent volumetric
study of serial MRIs of 11 (immunotherapeutically treated)
RE patients showed, that not only the ‘affected’, but also the
‘unaffected’ hemispheres underwent progressive atrophy—
the latter, however, at a significantly lower rate. The authors
suggested a Wallerian degeneration of commissural fibres,
the effect of the chronic epilepsy or the treatment as possible
reasons for this phenomenon, but argued against a similar
primary pathogenic process in both hemispheres (Larionov
et al., 2005). The term ‘bilateral RE’ should therefore be
reserved for cases with inflammatory lesions in both hemi-
spheres. Among the 200 RE cases reported in the literature,
bihemispheric involvement has been suggested in nine
(McLachlan et al., 1993; Chinchilla et al., 1994; DeToledo
and Smith, 1994; Tobias et al., 2003). Using the above cri-
teria, four cases (Chinchilla et al., 1994; Tobias et al., 2003)
are examples of true bilateral RE. Two other cases were
brothers with a presentation and course highly atypical for
RE. As concluded by the authors of that report, these patients
may have had a variant of RE (Silver et al., 1998). In the
remaining three, the diagnosis of ‘bilateral RE’ is in doubt
(McLachlan et al., 1993; DeToledo and Smith, 1994).
We conclude that bilateral RE is very rare. There is no
evidence for an inherent tendency of RE to spread to the
contralateral side after longstanding disease. Of note, the
above named four convincing cases had signs of bilateral
involvement earlier than 13 months after disease onset
(Chinchilla et al., 1994; Tobias et al., 2003). This seemingly
paradoxical finding is most important in view of surgical
indications: with over 10 years follow-up: no case of RE
initially cured by surgery from the epilepsy point of view
exhibited delayed relapse on the contralateral side, even
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when the affected hemisphere was not removed but purely
disconnected (Delalande and Bulteau, 2002).
RE with delayed seizures onset
An Israeli-German group studied two patients with progress-
ive hemiparesis and biopsy evidence of RE. These patients
developed unilaterally generated seizures only after several
months (Korn-Lubetzki et al., 2004).
Movement disorders in RE
Frucht (2002) presented a RE case with features of hemidy-
stonia and hemiathetosis in addition to EPC. On MRI, this
case had atrophy of the ipsilateral caudate and lentiform
nuclei in addition to one-sided cortical affection. In an
accompanying editorial, Andermann (2002) argued that
movement disorders in RE probably have been underreported
so far. An English group reporting on basal ganglia atrophy in
RE (most markedly of the caudate nucleus) identified two of
six cases initially presenting with hemidystonia (Bhatjiwale
et al., 1998).
Histopathology
The histopathological properties of RE have been described
in several studies. Using standard histochemical staining
techniques, Robitaille (1991) divided the Montreal material
of brain specimens into four groups that were found to cor-
respond to disease duration. Group 1 (earliest cases) revealed
inflammation with numerous microglial nodules, with or
without neuronophagia, perivascular round cells and glial
scarring. Group 2 was characterized by several microglial
nodules, cuffs of perivascular round cells, and at least one
gyral segment of complete necrosis. Group 3 included cases
displaying neuronal loss and gliosis with moderately abund-
ant perivascular round cells and few microglial nodules.
Finally, group 4 (latest cases) showed no or few microglial
nodules, neuronal loss and mild perivascular inflammation,
combined with various degrees of gliosis and glial scarring
(Robitaille, 1991). The round cell infiltrates in RE brains
consist almost exclusively of T lymphocytes (Farrell et al.,
1995). A large recent pathological study on the brain
specimens obtained at 45 hemidecortications confirmed
and refined Robitaille’s description of a stagewise course
(Pardo et al., 2004). Using a quantitative histopathological-
immunohistochemical approach, another group demonstrated
densities of T cells, microglial nodules and activated
astrocytes to be inversely correlated with disease duration
(Bien et al., 2002c). More recently, the same group extended
their immunohistochemical observations by characterizing
the majority of CD3 + cells (T cells) as CD8 + and containing
GrB + granules. A proportion of 7.0% of the CD8 + lympho-
cytes laid in apposition to neurons. Neurons were positive for
MHC class I. A few neurons were found to die by apoptosis.
These findings were interpreted as evidence for a cytotoxic
T cell reaction against neurons. Another diagnostically
relevant observation was that <5% of the CD68+ HLA-
DR + cells had macrophage morphology (the remainder
had microglial morphology). Inclusion bodies suggestive
of a viral infection have not been observed in RE. CD20 +
cells (B cells) and CD138 + cells (plasma cells) are extremely
rare. Signs of immunoglobulin deposits or activated comple-
ment were not found (Bien et al., 2002a).
Paraclinical features of RE
EEG features
As early as 4 months after disease onset in a series of
12 patients, Granata and colleagues found pronounced
EEG changes in their patients (Granata et al., 2003b).
They described polymorphic delta waves over the affected
hemisphere, mainly in a temporal and central location. Nine
out of 12 patients in addition had epileptiform abnormalities,
which in five cases tended to evolve into (subclinical) ictal
EEG patterns. During the disease course, the already initially
impoverished background activity showed further flattening
with persistence of the above described abnormalities. In the
majority of patients, contralateral asynchronous slow waves
and epileptiform discharges occurred. However, ictal patterns
were never recorded from contralateral electrodes. So and
Gloor (1991) found bilaterally independent ictal onsets in
three out of 32 patients. Andrews and co-workers described
serial EEGs in two patients. In both, they observed contralat-
eral epileptiform discharges which, in the long term, became
even more frequent than the ipsilateral ones (Andrews et al.,
1997). As in other conditions, EPC in RE is not always
accompanied by rhythmic EEG discharges on surface EEG
(Bancaud et al., 1970; So and Gloor, 1991).
In summary, there is evidence that the EEG may contribute
to the tentative diagnosis of RE already in early disease
stages. The following unihemispheric findings strongly sug-
gest RE: impairment of background activity and sleep
spindles; focal slow activity; multifocal ictal discharges;
and subclinical ictal discharges. In cases with the secure
diagnosis of RE, the documentation of an independent con-
tralateral seizure onset may raise the suspicion of bilateral
disease (see above).
MRI
Serial MRI findings of several patients have been published
during the last years. The Italian group (Chiapparini et al.,
2003; Granata et al., 2003b) found that, within the first
4 months after disease onset, the majority of patients exhibit
unilateral enlargement of the inner and outer CSF compart-
ments, most accentuated in the insular and periinsular
regions, with increased cortical or subcortical (or both) T2
(and FLAIR) signal. In addition, they observed atrophy of the
ipsilateral head of the caudate nucleus in the majority of
cases. A few patients transiently showed focal cortical swell-
ing on early scans. Subsequently, a spread of signal changes
and atrophy within the affected hemispheres was observed.
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The German group combined similar observations with quant-
itative evaluation of cell densities of inflammatory cells and
reactive astrocytes in brain specimens obtained from regions
with MRI abnormalities. In areas with increased signal, the
number of T cells, microglial nodules and GFAP + astrocytes
was increased compared with more chronically affected areas
with advanced atrophy and no more signal increase (Bien
et al., 2002c). Using a quantitative approach (calculation of
the ‘hemispheric ratio’, i.e. the ratio affected/unaffected hemi-
sphere on planimetry of axial and coronal slices including the
Sylvian fissure) to assess the temporal evolution of hemi-
atrophy, the same group found that most of the tissue loss
occurs during the first 12 months after onset of the acute
disease stage (Bien et al., 2002d ). However, it may, in
some cases, go on for several years (Bhatjiwale et al., 1998;
Chiapparini et al., 2003). In 11 immunotreated RE patients,
volumetric assessment of serial MRIs during early disease
stages revealed a median tissue loss of 29.9 cm3 per year
in the affected and of 6.8 cm3 in the unaffected hemispheres
(Larionov et al., 2005). Totally normal findings on very early
scans have been reported, but are rare (Geller et al., 1998;
Kaiboriboon et al., 2000; Lee et al., 2001). Gadolinium
enhancement is very rare in RE (Nakasu et al., 1997; Yacubian
et al., 1997; Bien et al., 2002c; Chiapparini et al., 2003).
Laboratory tests
No laboratory test is available to positively support the dia-
gnosis of RE. GluR3 antibodies in serum (and CSF alike) do
not discriminate between RE and noninflammatory epilepsy
(Wiendl et al., 2001; Mantegazza et al., 2002; Watson et al.,
2004). Moreover, the presence or absence of GluR3 antibod-
ies does not allow specific pathogenic clues in a given patient
and should not be used to select or exclude a specific
treatment.
CSF tests
The largest series of CSF tests has been reported by the
Montreal group. In 50% of the examinations, cell counts
and protein levels were in the normal range. In the remainder,
elevated cell counts (16–70 cells/ml, predominantly lympho-
cytes), an increased protein content (50–100 mg/dl) or a first
or midzone elevation of the colloidal gold curve were
observed. In only 15% of the abnormal CSF tests, all
three parameters were abnormal (Rasmussen et al., 1978;
Rasmussen and Andermann, 1989). Oligoclonal bands
were an inconsistent finding ranging from 0 to 67% in three
small series (Dulac et al., 1991; Grenier et al., 1991; Granata
et al., 2003b). Therefore, CSF standard tests are not suitable
to exclude or confirm the diagnosis of RE. Serological CSF
tests are usually applied to rule out a CNS infection by known
neurotropic agents.
Imaging studies other than morphological MRI
PET studies, almost exclusively performed using the tracer
fluorodeoxyglucose (FDG), showed abnormalities confined to
the affected hemisphere. In most cases, large areas of
hypometabolism were observed; in the remainder (mostly
‘ictal’ studies in patients with ongoing EPC), additional areas
of focal hypermetabolism were found (Hajek et al., 1991;
Hwang et al., 1991; Tampieri et al., 1991; Caplan et al.,
1996; Duprez et al., 1997; Banati et al., 1999; Kaiboriboon
et al., 2000; Fiorella et al., 2001; Lee et al., 2001; Chiapparini
et al., 2003; Maeda et al., 2003; Shah et al., 2003). In the
largest available study (15 patients), FDG-PET changes in
early stages (disease duration up to 1 year) were confined to
frontotemporal areas. In later stages, abnormalities also affec-
ted posterior cortical regions (Lee et al., 2001). One case
study suggested that FDG-PET-hypermetabolism correlates
with ongoing electrical seizure activity whereas methionin-
PET-hypermetabolism indicates areas of inflammation, but
this needs to be confirmed in larger patients group (Maeda
et al., 2003). It has been proposed that PET might guide brain
biopsy in cases with inconclusive or normal MRI findings,
especially in early stages (Lee et al., 2001).
With interictal and ictal single photon emission computed
tomography (SPECT), the same type of results and conclu-
sions have been reached as with PET (English et al., 1989;
Hwang et al., 1991; Burke et al., 1992; Buchhalter et al.,
1994; Duprez et al., 1997; Geller et al., 1998; Leach et al.,
1999; Hartley et al., 2002; Thomas et al., 2003; Chiapparini
et al., 2003).
Magnetic resonance spectroscopy (MRS) studies consist-
ently showed decreased N-acetyl-aspartate (NAA) levels and
increased (or normal) choline (cho) peaks resulting in a
decreased NAA/cho-ratio suggestive of neuronal loss or dys-
function (Matthews et al., 1990; Cendes et al., 1995; Geller
et al., 1998; Sener, 2000, 2003; Chiapparini et al., 2003).
Partly observed increased lactate peaks seemed to be asso-
ciated with the presence of EPC (Matthews et al., 1990;
Cendes et al., 1995; Sener, 2000; Chiapparini et al., 2003).
The present studies do not provide evidence for RE-specific
MRS abnormalities.
In conclusion, PET, SPECT and MRS techniques are not
suitable for defining the inflammatory nature of the condition.
They may, however, help in confirming the unihemispheric
nature in suspected early RE findings.
Brain biopsy
Brain biopsy is not required in all RE cases because other
criteria can be sufficient to diagnose the condition (see
Table 1). In ‘burnt out’ cases, brain biopsy may give non-
specific results and not lead to initiation of immunomodulat-
ory treatment (see below). In cases fulfilling neither the
diagnostic criteria listed in Table 1 Part A nor the non-
invasive criteria of Table 1 Part B as well as in less common
RE forms, brain biopsy can contribute considerably to dia-
gnostic certainty. Regarding brain biopsy, it has to be con-
sidered that abnormal and normal tissue elements may be
located in very close apposition (Robitaille, 1991; Farrell
et al., 1995; Pardo et al., 2004). Therefore, false negative
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results may be obtained in a small stereotactic needle biopsy.
If there are no contraindications, an open biopsy comprising
meninges, grey and white matter is preferable. If, in suspi-
cious cases, histology does not clearly show lymphocytic
inflammation and microglial (nodular) activation, evaluation
of serial sections may be necessary. More limited surgical
tissue collection, especially stereotactic procedures, increases
the risk of falsely negative results in an unacceptable manner.
Biopsy should be taken from a non-eloquent area where there
is increased T2/FLAIR signal on MRI (Bien et al., 2002c). In
cases without clear MRI lesions, PET or SPECT may be
helpful to determine the site of biopsy (Lee et al., 2001).
A gradient of inflammatory intensity from frontotemporal
to occipital areas, especially in early cases, has been observed
(Pardo et al., 2004). Therefore, frontal or temporal biopsies
are generally preferable (Lee et al., 2001). Cases with pre-
dominant parietal or occipital involvement, however, exist
(Bien et al., 2002d ). True histopathological differential dia-
gnoses to RE are not as numerous as sometimes assumed.
Chronic viral encephalitides (Booss and Esiri, 2003),
paraneoplastic encephalitis (Graus et al., 1990; Farrell
et al., 1995) and nonparaneoplastic limbic encephalitis
(Bien et al., 2000) need to be considered. If the results of
brain biopsy are inconclusive, further clinical and MRI
follow-up studies (e.g. every 6 months) are required to clarify
the nature of the disease.
Differential diagnoses
Differential diagnostic considerations usually need to cover:
(i) other unilateral neurological syndromes; (ii) other
reasons for EPC; or (iii) other inflammatory or infectious
diseases possibly mimicking RE. Potential differential dia-
gnoses and diagnostic steps to exclude these are summarized
in Table 2.
Diagnosis
The diagnosis of RE rests on clinical, electrophysiological
(EEG) and morphological studies (MRI, in some cases his-
topathology). In most chronic patients (i.e. after a disease
duration of >1 year), differential diagnoses are few. The
particular challenge, however, is the early recognition of
the disease, i.e. before progressive hemiatrophy and progress-
ive loss of neurological functions is evident. Early diagnosis
is desirable (Bien et al., 2002c,d; Granata et al., 2003b) as
immunosuppressive therapy may be most effective at this
time. Therefore, any formal diagnostic criteria should be
able to identify early as well as chronic cases. Age at onset
has not been included among the diagnostic criteria, although
it must be stressed that mostly RE starts in childhood.
Ten years ago, formal diagnostic criteria for RE were pro-
posed (Hart et al., 1994b). These criteria are still adequate in
cases with EPC (so-called group A). However, the non-EPC
group (group B) characterized by the authors only by the
combination of ‘focal epilepsy and biopsy evidence of [not
further specified] chronic encephalitis’ appears no longer
sufficiently sensitive or specific. We therefore propose the
diagnostic criteria given in Table 1. These criteria have the
following aims: (i) to allow the diagnosis at all stages;
(ii) to enable early diagnosis and thereby early decision about
specific treatment (epilepsy surgery or immunotherapy); and
(iii) to limit the use of brain biopsy to cases in which the
diagnosis cannot be clarified by other means. To achieve
these aims, the two-step approach outlined in the Table 1
has been designed. Any patient suspected to have RE should
be checked for the highly characteristic clinical, EEG and
MRI features listed in Part A. This is based on the results of a
recent Italian study (Granata et al., 2003b). If this combina-
tion is present, RE can be diagnosed without further follow-
up studies (to document the progressive course of the
Table 1 Diagnostic criteria for RE
RE can be diagnosed if either all three criteria of Part A or two out of three criteria of Part B are present. Check first for the features of Part A.
Then, if these are not fulfilled, of Part B. In addition: If no biopsy is performed, MRI with administration of gadolinium and cranial CT needs to
be performed to document the absence of gadolinium enhancement and calcifications to exclude the differential diagnosis of a unihemispheric
vasculitis (Derry et al., 2002).
Part A:
1. Clinical Focal seizures (with or without Epilepsia partialis continua) and Unilateral cortical deficit(s)
2. EEG Unihemispheric slowing with or without epileptiform activity and Unilateral seizure onset
3. MRI Unihemispheric focal cortical atrophy and at least one of the following:
Grey or white matter T2/FLAIR hyperintense signal
Hyperintense signal or atrophy of the ipsilateral caudate head
Part B:
1. Clinical Epilepsia partialis continua or Progressive* unilateral cortical deficit(s)
2. MRI Progressive* unihemispheric focal cortical atrophy
3. Histopathology T cell dominated encephalitis with activated microglial cells (typically, but not necessarily forming nodules)
and reactive astrogliosis.
Numerous parenchymal macrophages, B cells or plasma cells or viral inclusion bodies exclude the
diagnosis of RE.
*‘Progressive’ means that at least two sequential clinical examinations or MRI studies are required to meet the respective criteria. To
indicate clinical progression, each of these examinations must document a neurological deficit, and this must increase over time. To indicate
progressive hemiatrophy, each of these MRIs must show hemiatrophy, and this must increase over time.
460 C. G. Bien et al.
Table 2 Differential diagnoses to Rasmussen encephalitis
1. Unihemispheric epileptic syndromes Clinical and laboratory criteria
Cortical dysplasia (Desbiens et al., 1993) EPC usually starts in infancy or early childhood
Hemimegalencephaly (Fusco and Vigevano, 1991; Ishii et al.,
1995; Ohtsuka et al., 1999)
Tuberous sclerosis (Curatolo et al., 2002; Karenfort et al., 2002;
McClintock, 2002)
Sturge-Weber-syndrome (Arzimanoglou and Aicardi, 1992;
Kramer et al., 2000)
MRI with gadolinium
Stroke (Thomas et al., 1977; Nelson and Lynch, 2004) No progression on MRI
Hemiconvulsion-hemiplegia-epilepsy-syndrome (Kataoka et al.,
1988; Salih et al., 1997; Freeman et al., 2002)
Usually occurring in infancy
Initial (tonic-)clonic unilateral seizure, presenting as status
epilepticus
Early MRI: affection of whole hemisphere indicative of diffuse
cytotoxic edema
Thereafter persistent fixed or slightly improving
hemiparesis; hemispheric atrophy on MRI, and focal epilepsy
Tumour (Botez and Brossard, 1974) MRI
2. Epilepsia partialis continua (EPC) due to metabolic disorders
Diabetes mellitus: History
Ketotic/non-ketotic hyperglykemia (Singh et al., 1973; Singh
and Strobos, 1980; Sabharwal et al., 1989)
Blood tests
Type I diabetes and anti-GAD-65-antibodies (Barnett et al.,
2001)
Anti-GAD-65-antibodies
Renal or hepatic encephalopathy (Morres and Dire, 1989) History
Blood tests
3. Metabolic or degenerative progressive neurological diseases
MELAS and other mitochondriopathies (Andermann et al.,
1986; Antozzi et al., 1995; Schuelke et al., 1998; Kunz, 2002)
Blood-lactate (low sensitivity)
Mitochondrial DNA genetic testing for mutations
Muscle biopsy
Biochemical assessment of activity of mitochondrial enzymes
Alpers syndrome (Wilson et al., 1993; Worle et al., 1998;
Rasmussen et al., 2000)
History, progressive illness
EEG
MRI
Evoked potentials
Liver function tests
Biochemical assessment of activity of mitochondrial enzymes
Kufs disease (Gambardella et al., 1998) EEG
MRI
Evoked potentials
Skin biopsy
4. Inflammatory/infectious diseases
Cerebral vasculitis in systemic connective tissue disease (e.g.
lupus erythematosus) (Yoshida et al., 1995)
History
Other clinical features
Autoantibodies (ANA, ANCA)
‘Unihemispheric cerebral vasculitis mimicking Rasmussen’s
encephalitis’ (Derry et al., 2002)
CCT: calcifications
MRI: gadolinium enhancement
Brain biopsy
Subacute sclerosing panencephalitis (Lyon et al., 1977) and
other delayed subacute measles encephalitis with or
without immunodeficiency
History (vaccination status, early measles)
EEG: periodic discharges
Measles-antibodies in CSF
Paraneoplastic syndrome (Shavit et al., 1999) Tumour search
Onconeural antibodies (anti-Hu)
Russian spring summer meningoencephalitis (RSSE)
(Omorokow, 1927)
Occurs only in Siberia
History of tick-bites
Antibody reaction against the specific virus of RSSE
Brain biopsy: inclusion bodies
Multiple sclerosis (Hess and Sethi, 1990) History of previous episode(s)
Additional deficits
MRI
Oligoclonal bands
Evoked potentials
Creutzfeldt-Jakob-disease (Fried et al., 1995; Barnett et al.,
2001)
14–3–3 protein in CSF (cave: no absolute specificity;
14–3–3 status of RE patients unknown)
EEG
MRI
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disease) and without brain biopsy. The Part A criteria of
Table 1 are highly characteristic of early cases. To cover
also the RE cases with a different presentation, we added
Part B. If a patient fails to fulfil the criteria of Part A, he
or she should be checked for the criteria of Part B. The criteria
make use of the progressive nature of clinical and MRI defi-
cits or of brain biopsy. Criteria listed in Part B in addition to
Part A are highly likely to cover early cases, residual ‘burnt
out’ cases and less common forms of RE. Only the (extra-
ordinarily rare) cases of bilateral RE cannot be subsumed to
these criteria. On the other hand, fulfilment of these criteria
excludes other diseases. To our knowledge, only a histopatho-
logically demonstrated vasculitis of the type described by
Derry and colleagues in one single case could be mistaken
for RE on the basis of these criteria without brain biopsy
(Derry et al., 2002). The only non-invasively assessed dif-
ferences to RE in this case were gadolinium enhancement on
MRI and calcifications on cranial CT. It is therefore required
to rule out these features if RE is to be diagnosed without
histopathological examination.
Treatment
Treatment of RE pursues two goals: alleviation of the seizure
disorder and cessation of the progressive neurological deficit
(and associated loss of brain tissue). The concept of this two-
fold aim appears adequate in view of the timely dissociation of
epilepsy manifestation from the development of cerebral hemi-
atrophy and functional deterioration which occur in parallel
(Oguni et al., 1991; Bien et al., 2002d ). Epileptic seizures can
precede the other clinical features or RE; in the ‘prodromal
stage’ (Bien et al., 2002d ), they may in rare cases start several
months after the other signs and symptoms (Korn-Lubetzki
et al., 2004), and they may persist when the destructive
encephalitic process obviously has itself ‘burnt out’ (Oguni
et al., 1991). Thus, while both epilepsy and neurological
decline are most likely caused by the immunological process,
the specific mechanisms involved may not be totally the same
and may be differentially accessible for therapy.
Anti-epilepsy drug (AED) therapy
AEDs have consistently been found to be ineffective against
EPC, but to have some effect against the other seizure types
(Piatt et al., 1988; Dubeau and Sherwin, 1991; Topcu et al.,
1999). No anticonvulsive mono- or combination-therapy has
been described to be superior to other regimens (Dubeau and
Sherwin, 1991).
Epilepsy surgery
Epilepsy surgery has played a major role in seizure treatment
of RE since the 1950s. It remains the only ‘cure’ of the
disease progression, but not without neurological deficit.
Examination of histopathological specimens from surgery
permits the identification of the encephalitic nature of the
disease (Rasmussen et al., 1958). The earlier RE series almost
exclusively consisted of surgically treated cases, e.g. 47 out
of 48 patients in the Montreal series (Oguni et al., 1991). This
may have led to a somewhat biased view on the natural
history of RE with an over-representation of more severely
affected cases who may have been transferred to tertiary
epilepsy centres for presurgical (pre-hemispherectomy)
assessment more readily than cases with a milder disease
course. The results of focal resections in RE patients have
beendisappointing(Olivier,1991;Honavaretal., 1992).Hemi-
spherectomy and its modern variants (HE) (Villemure et al.,
1991; Delalande et al., 1992; Honavar et al., 1992; Schramm
et al., 1995, 2001; Villemure and Mascott, 1995; Carson et al.,
1996; Shimizu and Maehara, 2000), however, have been
found to be the so far only—and highly effective—therapy
to achieve seizure freedom. In RE patients, seizure freedom
rates between 62.5% and 85% (Honaver et al., Vining et al.,
1997; Delalande and Bulteau 2002; Villemure, 2002; Granata
et al., 2003b; Kossoff et al., 2003; Jonas et al., 2004; Pulsifer
et al., 2004) have been reported. In recent HE series, mostly
disconnective techniques have been applied (see below). The
mortality in HEs done on RE patients in such series has been
reported as 0% (Devlin et al., 2003; Kossoff et al., 2003; Jonas
et al., 2004) to 4% (Villemure, 2002), and the complication rate
(excluding hydrocephalus requiring shunt placement) as 0%
with partly resective and partly disconnective techniques
(Villemure 2002; Jonas et al., 2004) to 22% with resective
techniques only (Vining et al., 1997).
Such a wide range in seizure control and complications is
striking. One important variable that accounts for this is the
surgical methodology utilized, whether based on resection or
disconnection. As far as complications are concerned, there
Table 2 Continued
HIV (Ferrari et al., 1998; Bartolomei et al., 1999) Blood antibody tests
Cat scratch disease (Nowakowski and Katz, 2002; Puligheddu
et al., 2004)
History
Cutaneous papules, lymphoadenopathy
Serology (Bartonella henselae)
5. Other
Proconvulsive drugs: History
Metrizimide (Shiozawa et al., 1981)
Penicillin, Azlocillin-Cefotaxim (Wroe et al., 1987)
Bone marrow transplant (Antunes et al., 2000) History
Gliomatosis cerebri (Shahar et al., 2002) MRI
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is accumulating evidence that disconnective techniques
(functional hemispherectomy and hemispherotomy) are asso-
ciated with a lower incidence of complications compared
with anatomical hemispherectomies (Villemure, 1997a,b).
A possible disadvantage of those techniques compared
with anatomical hemispherectomy is that incomplete discon-
nections may give rise to residual seizures. In experienced
centres, the technique should not influence seizure outcome,
but only the rate of complications.
Timing of surgery
There is a controversy as to whether HE should be proposed
early in the disease course (Vining et al., 1997) or only when
the neurological deficits, which inevitably induced by the
operation (loss of fine finger movements, hemianopia and,
if the dominant hemisphere is affected, aphasia), have been
brought about by the natural course of the disease (Villemure
et al., 1991; Honavar et al., 1992; Rasmussen, 1993). The
latter standpoint is supported by the observation that not all
patients proceed to maximal deficits, especially—but not
exclusively—in the late-onset form (Oguni et al., 1991;
Bien et al., 2002d ). The advocates of early surgery have
argued that the advantages of seizure freedom and a post-
HE overall functional improvement justify the ‘anticipation’
of ‘inevitable’ consequences of the disease (Vining et al.,
1993, 1997).
The decision will be influenced by the dominance of the
hemisphere and be made only after extensive review and
discussion with the child and family. It requires information
about the deficits and advantages caused by the surgical pro-
cedure in relation to the disease course without surgical inter-
vention. The consequences of a HE in RE can be summarized
as follows.
Motor outcome after HE
After HE, patients will have a spastic hemiplegia of the
contralateral side with loss of the (functionally highly relev-
ant) fine motor hand movements (van Empelen et al., 2004).
However, only a minority of patients are unable to walk
without the use of assistive devices. As reported in a large
recent HE series (consisting not only of RE cases), patients
not achieving ambulation post-operatively were either
immobile pre-operatively due to the underlying disease pro-
cess, or had major post-operative complications, or suffered
from persistent disabling seizures (Kossoff et al., 2003).
Hemianopia
Another inevitable consequence of HE is a homonymous
hemianopia to the contralateral side. Because of insufficient
cooperation of many patients, it is often difficult to clarify if a
hemianopia is already present due to the disease process itself
when HE is considered. However, most clinicians treating RE
patients feel that the risk of inducing hemianopia which is not
present pre-operatively is tolerable because it does not interfere
with the patient’s overall functioning (Villemure et al., 1991).
Language
More difficult is the situation in patients with involvement of
the hemisphere dominant for language functions. The most
reliable test for language dominance is the Wada test.
Language functional MRI (fMRI) testing may become an
additional, non-invasive tool for assessment of language
function lateralization. However, its applicability may be
impaired by the reduced ability of patients to follow the
instructions and the limited comparability of the two hemi-
spheres due to the unilateral atrophy (Hertz-Pannier et al.,
2002). Further clues towards language lateralization may be
derived from interictal and ictal language dysfunction. A
group of RE patients with left-sided hemidecortication (with-
out information on preoperative language dominance by
Wada testing) showed impairment of expressive and recept-
ive language functions compared with RE patients after
right-sided HE. There were no significant differences in
general intelligence, receptive language, visual motor-skills,
behaviour or adaptive/developmental functioning between
the two groups (cross-sectional data). Compared with their
presurgical performance, the patients having undergone left-
sided surgery deteriorated only in expressive language
performance in a significant manner but not in general intel-
ligence, receptive language, visual motor-skills, behaviour
or adaptive/developmental functioning (longitudinal data)
(Pulsifer et al., 2004). The risk of post-operative language
deficits, however, is not uniform for all patients. Particular
concern regarding post-operative language deficits arises in
cases with disease onset after the age of 4–6 years. One out of
eight left-sided affected RE patients with a disease onset
before the age of 6 years showed left-sided language dom-
inance on Wada testing, whereas in eight patients starting
above the age of 6 years, this ratio was exactly vice-versa
(Taylor, 1991). Based on this and other observations (e.g.
Branch et al., 1964; Ogden, 1988; Boatman et al., 1999),
it is commonly assumed that the ability to establish (almost)
complete language representation in the hemisphere not ori-
ginally determined for this ends during the age period
between 4 and 6 years. Six patients (with assumed left-
sided dominance) underwent left-sided hemidecortication
after an RE onset between 5.3 and 10.4 years. At 9–13 months
of follow up, patients re-achieved their pre-operative scores
on some tests of receptive language subfunction. However,
they largely produced only telegraphic speech output
(Boatman et al., 1999). In a bilingual girl with RE onset at
age 5 years, severe deficits in both languages, especially in
expressive functions, were observed after a left-sided HE at
the age of 10 years (Trudeau et al., 2003). In contrast to these
cases, two RE cases with late language transfer have also
been reported. In one, manifestation of left-hemispheric RE
was at 8 years of age. Compared with his pre-operative per-
formance, the patient showed improved language perform-
ance after left-sided HE at the age of 15 years. In this patient,
left-sided language dominance had been assessed by
Wada testing at the age of 9 years and right sided dominance
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immediately pre-operatively (Loddenkemper et al., 2003).
The second with disease onset at the age of 11 years became
profoundly aphasic and underwent HE at the age of sixteen.
Post-operatively, language dramatically improved (Telfeian
et al., 2002). A functional correlate for transfer of language
functions in RE was suggested by Hertz-Pannier and col-
leagues in their report of a patient with onset of left sided
RE at age 5.5 years. This boy underwent left sided HE at the
age of 9 years. The post-operative course was like that of
Boatman’s patients (see above). Interestingly, the post-
operative improvement mainly of receptive language func-
tions was reflected in a right-hemisphere inferior frontal,
temporal and parietal activation on fMRI in areas not activ-
ated during a fMRI obtained early in the disease course
(Hertz-Pannier et al., 2002).
Studies on the HE outcome in children with an onset of
left-sided RE prior to the age of 4 years are rare. There are
some reports on children with left-sided RE or other left-
hemispheric diseases acquired very early in life undergoing
hemispherectomy later on. Their language outcome following
HE was better than in patients with disease onset after the age
of 6 years; however, it was still below the normal age range
(Ogden, 1988; Stark et al., 1995; Stark and McGregor, 1997).
It cannot be deduced from the existing literature if the age at
surgery is a relevant prognostic factor for language outcome
in this patient group (Vargha-Khadem et al., 1991; Stark and
McGregor, 1997).
The question of when and if HE on the dominant side is
appropriate causes difficulties and often controversies. In the
mid- to long-term course of RE, deficits may fluctuate over
time and, in some conservatively treated patients, at least
temporary improvement of previously impaired functions
have been reported (Andrews et al., 1996; Hart et al.,
1994b; Bien et al., 2004). We suggest that in cases of
dominant hemisphere involvement, HE is indicated in cases
of very severe intractable epilepsy (i.e. manifest or impending
complications due to the seizure activity) or with severe
aphasia, which has been stable for at least some months
(to exclude only temporarily aphasic patients). In children
with a disease onset prior to the age of 4 years, i.e. without
fixed hemispheric lateralization, the decision in favour of or
against HE should primarily be based on seizure severity and
motor assessment rather than language considerations. Any
decision made must be made on a multidisciplinary basis,
individualised to the patient in question and only after full
discussion with the family.
Immunotherapy
Immunosuppressive, immunomodulatory and antiviral
treatment approaches have been applied, and several case
reports and a few case series have been reported with
variable and sometimes conflicting results (for a review,
see Bien et al., 2002b). Here, treatments with <6 reported
patients in the literature will not be discussed further. This
leaves the following regimens as the basis for our
recommendations: (i) corticosteroids (Chinchilla et al.,
1994; Hart et al., 1994b; Granata et al., 2003a); (ii) intravenous
immunoglobulins (IVIG) (Walsh, 1991; Hart et al., 1994b;
Wise et al., 1996; Leach et al., 1999; Villani et al., 2001;
Granata et al., 2003a); (iii) corticosteroids plus IVIG
(Hart et al., 1994b; Krauss et al., 1996; Vinjamuri et al.,
2000); (iv) plasmapheresis (PEX) or protein A IgG immuno-
adsorption (PAI) (Andrews et al., 1996; Palcoux et al., 1997;
Antozzi et al., 1998; Granata et al., 2003a); and (v) tacrolimus
(Bien et al., 2004).
Corticosteroids
Prednisolone/prednisone started at high doses and slowly
tapered down have been reported to have beneficial effects
on seizures and neurological functions in several series, par-
ticularly when started early in the course (Chinchilla et al.,
1994; Hart et al., 1994b; Granata et al., 2003a). Not unex-
pectedly, serious side effects partly necessitating steroid
withdrawal have been noticed; fluid retention/Cushing’s
syndrome in all patients and, in single cases, psychosis, beha-
vioural abnormalities, septicaemia, osteoporosis, hyperten-
sion and candidiasis (Chinchilla et al., 1994; Hart et al.,
1994b; Granata et al., 2003a). For long-term steroid therapy,
it has been recommended to start with boluses of intravenous
(i.v.) methylprednisolone [e.g. 400 mg/m2/day (Hart et al.,
1994b) or, in children, 20 mg/kg/day (Granata et al., 2003a)]
and then to introduce 1–2 mg/kg/day oral prednisolone or
prednisone (Hart et al., 1994a; Granata et al., 2003a). This
dose should be slowly reduced, ideally to a dose below the
threshold of Cushing’s syndrome. Short-term steroid bolus
administration (dosing as above) has been found to be effect-
ive in blocking status epilepticus (Hart et al., 1994b; Granata
et al., 2003a).
IVIG
Good effects of IVIG on seizures and neurological functions
were reported in some case studies and in Hart’s large series
where IVIG is recommended as the first-line immunotherapy
(Hart et al., 1994b). In recent years, favourable responses of
adult cases (Leach et al., 1999; Villani et al., 2001) have lead
to the proposal IVIG as first-line treatment especially in late-
onset cases (Granata et al., 2003a). Single responding cases
with a follow-up of >12 months have been reported (Leach
et al., 1999; Granata et al., 2003a). The recommended
dosing scheme is to start with three to five consecutive infu-
sions of 0.4 g/kg/day and to proceed with a monthly dose of
0.4–2.0 g/kg distributed over 1–5 consecutive days. Side
effects of IVIG treatment are rare.
IVIG plus steroid
In case of insufficient effect of IVIG, Hart et al. (1994b)
recommended a combination of 0.4 g/kg/month IVIG plus
corticosteroids (dosing as above).
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PEX/PAI
PEX cycles have been performed at a frequency of three to six
single volume exchanges on consecutive or alternate days,
repeated every 2 to 8 weeks (Andrews et al., 1996; Granata
et al., 2003a). Selective periodic immuno-adsorption with
protein A has been used as a long-term management with
positive results in adolescent-adult onset patients (Antozzi
et al., 1998; Antozzi, 2004). PEX/PAI improved neurological
function and seizure frequency in some patients during the
weeks following the intervention that could be reinstituted by
repeat treatment. There is very limited experience with long
term PEX/PAI treatment in RE (Granata et al., 2003a).
Tacrolimus
Based on the observation of T lymphocyte mediated cell
damage in RE brains, (Bien et al., 2002a) performed long-
term treatment with the T cell inhibiting immunosuppressant
tacrolimus (oral application) in seven patients (median
follow-up 25.4 months, range 12.4–32.0 months). In this trial,
for the first time a surrogate marker of the RE disease process
(the calculation of the hemispheric ratio from serial MRIs)
was used as an additional outcome parameter. Also, for the
first time, a control group consisting of 12 historical untreated
patients was compared with the treatment group. The
tacrolimus patients had a superior outcome regarding neuro-
logical function and progression rate of cerebral hemiatrophy
on MRI, but no better seizure outcome. Their cognitive out-
come was surprisingly good (only one patient deteriorated).
None of the tacrolimus patients, but seven out of 12 control
patients proceeded to hemispherectomy. Relevant tacrolimus
side effects were not observed (Bien et al., 2004).
Conclusions and recommendations for
treatment of RE
Based on the reported experience with RE treatments, we
recommend the following therapeutic pathway of the
figure for patients fulfilling the diagnostic criteria for RE
(Fig. 1).
Once a patient is diagnosed as having RE (field 1 in Fig. 1),
it should be assessed if HE would lead to a relevant impair-
ment of his/her motor or language functions according to the
above summarized existing experience on the consequences
of HE (field 2 in Fig. 1). If no relevant deterioration is to be
expected (because the disease itself has already caused pro-
found impairment) and the patient is suffering from intract-
able seizures (field 3 in Fig. 1), HE should be proposed (field
4 in Fig. 1). If there are no (more) intractable seizures (e.g. in
‘burnt out’ cases), no specific therapy is suggested (field 5 in
Fig. 1). If in those patients intractable seizures recur (field 6 in
Fig. 1), HE should be proposed (field 4 in Fig. 1).
In RE patients at risk of relevant functional deterioration by
HE, i.e. with retained motor or language skills relevant for
every-day function, it should be assessed if they are still in the
course of ongoing deterioration (field 7 in Fig. 1). Indicators
for ongoing progression are an increase of functional impair-
ment (especially: EPC or high seizure frequency; increase of
hemiparesis, cognitive or language deficits) or of cerebral
hemiatrophy during the last 6–12 months. If the patient
has been in a stable condition during this period, no specific
treatment is recommended because it can be assumed that he
or she has reached the residual stage of the disease (field 8 in
Fig. 1). If there are, however, signs of continuous deteriora-
tion, the patient should be started on immunotherapy (field 9
in Fig. 1). Patients on immunotherapy (field 9 in Fig. 1) as
Fig. 1 Therapeutic approach to the RE patient.
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well as those without specific treatment because of apparent
inactivity of the destructive disease process (field 8 in Fig. 1)
should be monitored for further progression. We suggest
examining those patients every 6–12 months clinically and
by brain MRI. If significant deterioration becomes evident,
the patient should again be evaluated for eligibility for HE as
described above (field 2 in Fig. 1). If there is still a risk of
impairment by HE, the patient should proceed to immuno-
therapy (field 9 in Fig. 1) [because the criteria of ongoing
progression (field 7 in Fig. 1) is fulfilled in these cases as
evident from their passing through field 10 in Fig. 1], i.e.
immunotherapy should either be initiated (if patients have
been on no specific treatment before i.e. field 8 in Fig. 1)
or changed (if patients have received immunotherapy before,
field 9 in Fig. 1). Regular follow-up studies to detect a
relevant disease progression (field 10 in Fig. 1) should be
performed. It is not clear to date after what period of stabil-
ization on immunotherapy this kind of treatment should be
discontinued (field 11 in Fig. 1). It may be guessed that
2–3 years in a stable condition are the minimal time period
before trying to taper any immunotreatment. If long-term
steroid administration is performed, the lowest possible
dose to maintain therapeutic benefit should be commenced.
Again, we recommend regular follow-up examinations.
In general, patients having seizures should be treated with
AEDs at any stage of the disease to reduce the frequency of
non-EPC seizures. We recommend steroid boluses or PEX/
PAI for periods of status epilepticus. There is, at present,
insufficient evidence to give specific guidelines regarding
the choice of the initial kind of immunotreatment. In the light
of the present experience, steroids, IVIG, PEX/PAI or
tacrolimus appear to be most suitable. At present, there is
no evidence in favour of one specific treatment over the
others; moreover, none of them has been proven to be an
alternative to surgery in halting the disease process.
Our recommendation to reserve HE for patients with
profound neurological deficits in order to avoid iatrogenic
harm to them needs to be considered in relative terms in
any patient who is severely disabled by seizures or side
effects of the AEDs. In those patients, the consequences of
HE should be weighted against the possibly deleterious
consequences of frequent or even continuous intractable
seizures.
Prospects of therapeutic research in RE
Previous experience
Up to now, case reports or uncontrolled patient series have
provided the available evidence on surgical and immunolo-
gical treatments of RE. This limitation is due to the small
number of RE patients. Insofar, RE shares the typical prob-
lems of other orphan diseases. From the existing reports, it is
obvious that HE offers a good prospect of achieving seizure
freedom, albeit at the price of induction of severe deficits.
On the other hand, it is unclear if immunotherapies are
able to modify the long-term outcome of RE patients. An
immunotherapy may prolong the period of high seizure fre-
quency and deterioration without finally preventing the loss
of function. Thus, the patient will at last be offered radical
surgery, that is, the very treatment that had been withheld
at the earlier stage in view of the preserved language and
motor functions. However if this is found for one immuno-
therapeutic regimen, another one may still be beneficial. At
present, it is far from clear how to rank the immunotherapies
described above in RE.
Recommended future therapeutic research
From these and other considerations, the following general
principles of future therapeutic research are outlined:
(i) Any kind of valid therapeutic report should inform
about the long-term outcome of the patients treated,
i.e. to cover a follow-up of at least 1 or 2 years.
(A rapid beneficial effect, even if short-lived, of a treat-
ment with a known mode of action may provide hints
toward the pathogenesis of the disease studied. A report
on such a short term-observation does, however, not
provide meaningful therapeutic information in a chron-
ically progressive disorder.)
(ii) Given the variability of the RE course, only studies on
patient cohorts (not on single cases) will provide rel-
evant new information.
(iii) For any such study of a treated patient cohort, a control
group will be necessary. As a minimum requirement, an
adequate historical control group should be retrospect-
ively analyzed. (Comparisons with historical non-
operated and non-immunotreated controls might turn
out to be particularly meaningful since placebo-
controlled studies are no longer conceivable in RE.
Also, there are unlikely to be long-term courses of
untreated patients in the future—whereas this was
not so rare in the past when the disease and its treatment
options were less well known than today.) The ideal
type of study would be a controlled clinical trial in a
prospective, randomized, multi-centre manner. Even
though such a trial is conceivable, it will be logistically
difficult to perform.
(iv) Which patients should be included? Because of the non-
uniform activity of the pathological process during the
disease course and in different age groups, only patients
at similar disase stages and of similar ages should be
compared.
(v) What kind of interventions should be compared in such
a trial? A design with a placebo control group in this
progressive condition will be unacceptable for ethical
committees and potential study candidates in the light
of existing reports on therapies that may prevent
disability. Therefore, comparative trials will be the
only realistic option. As to the type of the interventions
to be compared, a prospective randomised comparison
of surgical and immunotherapeutical treatments is
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unacceptable in the light of the considerations above.
According to the therapeutic pathway presented here
(Fig. 1), there will be only very rarely, if ever, a
situation in which HE and long-term immunotreatment
will appear to be equally beneficial for the patient.
This leaves the prospective, randomized long-term
comparison of currently accepted treatments to each
other or of a ‘new’ therapy to one of the accepted regi-
mens as the most desired future type of therapeutic trial
in RE. It should include patients during early rather than
late periods of RE. More than 1 year or so after the onset
of the acute stage, many patients will have entered the
residual stage and will therefore either be eligible for
HE or will no longer benefit from immunotherapy or
both. A double-blind design may not be feasible in
such a long-term study, especially if a drug like IVIG
is tested.
(vi) What are appropriate efficacy parameters? The most
relevant and best assessable clinical measures are
regularly assessed degree of hemiparesis and seizure
frequency. Periodic testing of neuropsychological func-
tions or health-related quality of life may be further
options. A study with regular follow-up visits and
pre-defined exit criteria (e.g. a certain increase in the
degree of hemiparesis) may be most adequate. This
would permit a timely consideration of HE or change
of immunotherapy according to the therapeutic path-
way given above if a trial drug fails to stop the chronic
progression.
(vii) An additional MRI surrogate measure of the destructive
disease process assessing the degree of hemiatrophy
over time during the study course might further enhance
the validity of such a study.
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